Featured Research

from universities, journals, and other organizations

Past HIV vaccine trials reveal new path to success

Date:
March 19, 2014
Source:
Duke Medicine
Summary:
A subclass of antibodies associated with an effective immune response to an HIV vaccine has been discovered by a multi-national research team. The finding helps explain why a combination of two vaccines was able to show some effect, when one vaccine alone did not. The study also provides key insights that could aid development of new vaccines.

A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine.

The finding, reported in the March 19, 2014, issue of the journal Science Translational Medicine, helps explain why a combination of two vaccines was able to show some effect, when one vaccine alone did not. The study also provides key insights that could aid development of new vaccines.

“More is not always better with an antibody response,” said senior author Georgia D. Tomaras, Ph.D., director of the Laboratory of Immune Responses and Virology at Duke Human Vaccine Institute. “Instead, it’s the underlying quality of the immune response. Going forward with other vaccine trials, it will be important to know the subclass, specificity and antiviral functions of antibodies that are induced.”

Tomaras and colleagues examined two HIV vaccine trials previously conducted in Thailand. The first trial they revisited, called VAX003, was completed in 2003 and studied an investigational vaccine among intravenous drug users. The vaccine was found to be ineffective.

The second trial, known as RV144, concluded in 2009 and involved more than 16,000 adults. It used two vaccines in combination – one as the prime vaccine and the second as a boost. The boost was the same investigational vaccine used in the earlier VAX003 trial. In the RV144 study, the combination vaccine was 31.2 percent effective at preventing HIV infection – a success rate that was unprecedented, but considered too low to advance the vaccine to common use.

In both trials, the vaccines induced the production of antibodies that targeted the same region of the HIV virus. In fact, the vaccine used in the VAX003 trial actually elicited higher levels of most of the antibodies than the prime/boost combination of the more successful RV144 trial.

But there was one exception. Tomaras and colleagues found that participants in the RV144 vaccine trial were more likely to have HIV-specific IgG3 antibodies, compared to individuals in the VAX003 trial. The HIV-specific IgG3 response correlated with decreased infection risk, but the effect waned over time, similar to the declining efficacy observed in the RV144 trial.

“HIV-1 specific IgG3 is one biomarker that can be evaluated in further vaccine candidates. It provides a specific way to benchmark HIV-1 vaccine candidates against the one partially efficacious vaccine to date.” Tomaras said.


Story Source:

The above story is based on materials provided by Duke Medicine. Note: Materials may be edited for content and length.


Journal Reference:

  1. N. L. Yates, H.-X. Liao, Y. Fong, A. deCamp, N. A. Vandergrift, W. T. Williams, S. M. Alam, G. Ferrari, Z.-y. Yang, K. E. Seaton, P. W. Berman, M. D. Alpert, D. T. Evans, R. J. O'Connell, D. Francis, F. Sinangil, C. Lee, S. Nitayaphan, S. Rerks-Ngarm, J. Kaewkungwal, P. Pitisuttithum, J. Tartaglia, A. Pinter, S. Zolla-Pazner, P. B. Gilbert, G. J. Nabel, N. L. Michael, J. H. Kim, D. C. Montefiori, B. F. Haynes, G. D. Tomaras. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Science Translational Medicine, 2014; 6 (228): 228ra39 DOI: 10.1126/scitranslmed.3007730

Cite This Page:

Duke Medicine. "Past HIV vaccine trials reveal new path to success." ScienceDaily. ScienceDaily, 19 March 2014. <www.sciencedaily.com/releases/2014/03/140319195723.htm>.
Duke Medicine. (2014, March 19). Past HIV vaccine trials reveal new path to success. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/03/140319195723.htm
Duke Medicine. "Past HIV vaccine trials reveal new path to success." ScienceDaily. www.sciencedaily.com/releases/2014/03/140319195723.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins